KDMN News and Press, Kadmon Holdings Inc. From 07/22/21

Should you buy penny stocks today ? If you like volatility, quick gains, handle high-risk situations and understand trading basics, I say, why not? But the stock market today isn’t like it was even just a year ago. The fact is, millions of new traders have flooded into the market...

- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that dat...

Gainers: [[IMRA]] +6.3%. [[SKYW]] +5.9%. [[ZUMZ]] +4.0%. [[BSET]] +3.58%. [[SFIX]] +3.3%.Losers: [[MDWD]] -7.8%. [[EVK]] -5.2%. [[AACG]] -4.2%. [[LIZI]] -3.4%. [[KDMN]] -3.3%. For further details see: IMRA, ZUMZ, MDWD and EVK among after-hours movers

Stanislau Kharytanovich/iStock via Getty Images The shares of Kadmon Holdings ([[KDMN]] +18.0%) jumped higher in reaction to the marketing approval granted by the FDA for Rezurock (Belumosudil) the company’s oral treatment developed for chronic graft-versus-host disease ((cGVHD)). Acco...

- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on Monday, July 19, 2021 at 8:00 a.m. ET - NEW YORK, NY / ACCESSWIRE / July 16, 2...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Dan Loeb's 13F portfolio value increased from ~$13B to $14.83B this quarter. The number of positions increased from 73 to 125. Third Point added Paysafe, CoStar Group, and Uber Technologies while dropping Alibaba Group Holdings and Fidelity National Information Services. The top t...

- Results Demonstrate KD033 was Well Tolerated in All Patients through Initial Dose Cohorts, Allowing for Continuation of Dose Escalation - NEW YORK, NY / ACCESSWIRE / May 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced initial safety data from the ongoing Phase 1 clinica...

Kadmon (KDMN): Q1 GAAP EPS of -$0.17 beats by $0.01.Revenue of $0.56M (-91.7% Y/Y) misses by $0.13M.Press Release For further details see: Kadmon EPS beats by $0.01, misses on revenue